Tag #Eli Lilly

Showing 1 to 12 of 27 results

theguardian.com

🌐 85% Global Worthiness

Sep 24, 13:21

Eli Lilly CEO Calls UK "Worst in Europe" for Drug Prices, Threatening Investment

Eli Lilly's CEO, Dave Ricks, criticized the UK's drug pricing regime as the "worst in Europe," citing it as a reason for the pharmaceutical industry's withdrawal of nearly £2 billion in planned investments.

Eli Lilly CEO Calls UK "Worst in Europe" for Drug Prices, Threatening Investment

Eli Lilly's CEO, Dave Ricks, criticized the UK's drug pricing regime as the "worst in Europe," citing it as a reason for the pharmaceutical industry's withdrawal of nearly £2 billion in planned investments.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of the UK's drug pricing policies on pharmaceutical investment and new drug availability?

Pharmaceutical companies, including Eli Lilly, have withdrawn approximately £2 billion in planned UK investments this year due to the UK's strict pricing regime. This policy may lead to reduced availability of new drugs in the UK.

nbcnews.com

🌐 85% Global Worthiness

Aug 27, 04:18

S&P 500 Rises Despite Concerns Over Fed Independence

The S&P 500 closed up 0.41% at 6,465.94 on Tuesday, boosted by Nvidia and Eli Lilly, despite concerns about the Federal Reserve's independence after President Trump fired a governor; investors anticipate a September interest rate cut.

S&P 500 Rises Despite Concerns Over Fed Independence

The S&P 500 closed up 0.41% at 6,465.94 on Tuesday, boosted by Nvidia and Eli Lilly, despite concerns about the Federal Reserve's independence after President Trump fired a governor; investors anticipate a September interest rate cut.

Progress

36% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

How do Nvidia's upcoming earnings and Eli Lilly's drug announcement contribute to the overall market performance?

Nvidia's upcoming earnings report is highly anticipated, potentially impacting the AI stock market rally. The removal of the Fed governor adds to existing anxieties about the Fed's independence from political influence, potentially affecting monetary policy. Traders are currently pricing in a September interest rate cut despite persistent inflation.

theguardian.com

🌐 85% Global Worthiness

Aug 14, 22:16

Mounjaro Price Hike in UK Reaches 170% Amidst Trump's Drug Pricing Pressure

Eli Lilly will increase the price of its weight-loss injection Mounjaro in the UK by up to 170% from September, aligning it with other European markets despite the NHS not paying the increased price; this follows pressure from Donald Trump to lower US drug prices by reducing prices in Europe.

Mounjaro Price Hike in UK Reaches 170% Amidst Trump's Drug Pricing Pressure

Eli Lilly will increase the price of its weight-loss injection Mounjaro in the UK by up to 170% from September, aligning it with other European markets despite the NHS not paying the increased price; this follows pressure from Donald Trump to lower US drug prices by reducing prices in Europe.

Progress

48% Bias Score

ShareSaveArticle

12345678

Previous 1 of 8 Next

What are the immediate consequences of Eli Lilly's decision to increase Mounjaro's price in the UK?

The price of Mounjaro, a weight-loss injection, will increase by up to 170% in the UK starting September, raising the highest dose from £122 to £330 per month. This aligns the UK price more closely with other European markets, a move Eli Lilly says is necessary despite the NHS not paying the increased price. Private healthcare providers may negotiate separate discounts.

abcnews.go.com

🌐 85% Global Worthiness

Aug 7, 16:18

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly's Phase 3 trial of the oral GLP-1 drug orforglipron showed an average weight loss of 27.3 pounds (12% body weight) in over 3,100 overweight or obese adults over 72 weeks, with cardiovascular benefits and side effects similar to injectable GLP-1s; the company plans to seek regulatory approv...

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly's Phase 3 trial of the oral GLP-1 drug orforglipron showed an average weight loss of 27.3 pounds (12% body weight) in over 3,100 overweight or obese adults over 72 weeks, with cardiovascular benefits and side effects similar to injectable GLP-1s; the company plans to seek regulatory approv...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key findings from Eli Lilly's Phase 3 trial on the efficacy and safety of orforglipron in weight loss and cardiovascular health?

Eli Lilly announced that its new oral GLP-1 pill, orforglipron, resulted in an average weight loss of 27.3 pounds over 72 weeks in a Phase 3 trial involving over 3,100 overweight or obese adults. The highest dose (36mg) led to approximately 12% body weight reduction. This offers a potential non-injectable alternative to existing treatments.

pt.euronews.com

🌐 85% Global Worthiness

Jul 25, 22:12

EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Safety Protocols

The European Medicines Agency (EMA) conditionally approved the Alzheimer's drug donanemab (Kisunla) for patients with one or zero copies of a gene linked to increased risk, after initially rejecting it due to the risk of brain swelling and bleeding; the drug will be available only under strict safet...

EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Safety Protocols

The European Medicines Agency (EMA) conditionally approved the Alzheimer's drug donanemab (Kisunla) for patients with one or zero copies of a gene linked to increased risk, after initially rejecting it due to the risk of brain swelling and bleeding; the drug will be available only under strict safet...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What factors contributed to the EMA's initial rejection of donanemab and its subsequent conditional approval?

The EMA's reversal highlights the complex balancing act between providing access to potentially life-changing treatments and mitigating serious side effects. The decision to allow use in patients with one copy of the APOE ε4 gene, only under strict monitoring and with lower initial doses, reflects an attempt to manage the risk of ARIA while offering benefit to those who might otherwise not receive the treatment. This approach mirrors a similar decision on the drug Leqembi, suggesting a developing framework for approving such high-risk treatments.

theglobeandmail.com

🌐 85% Global Worthiness

May 16, 16:10

Novo Nordisk CEO Steps Down Amidst Market Challenges and Competition

Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to market challenges and declining share prices after Eli Lilly's Zepbound surpassed Wegovy in US prescriptions since mid-March; former CEO Lars Rebien Sorensen will join the board as an observer.

Novo Nordisk CEO Steps Down Amidst Market Challenges and Competition

Novo Nordisk CEO Lars Fruergaard Jorgensen resigned Friday due to market challenges and declining share prices after Eli Lilly's Zepbound surpassed Wegovy in US prescriptions since mid-March; former CEO Lars Rebien Sorensen will join the board as an observer.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary reason for Novo Nordisk's CEO stepping down, and what are the immediate consequences for the company?

Novo Nordisk CEO Lars Fruergaard Jorgensen stepped down due to market challenges and declining share price. Eli Lilly's obesity drug Zepbound surpassed Wegovy in US prescriptions since mid-March, impacting Novo Nordisk's market share. The company's share price is down 32% year-to-date and 59% from its all-time high.

theguardian.com

🌐 85% Global Worthiness

Sep 17, 01:17

Orforglipron: A New Daily Pill for Weight Loss Shows Promising Results

A 72-week trial of 3,127 obese adults found that orforglipron, a new daily weight-loss pill, led to significant weight loss, with 18.4% of those on the highest dose losing 20% or more of their body weight.

Orforglipron: A New Daily Pill for Weight Loss Shows Promising Results

A 72-week trial of 3,127 obese adults found that orforglipron, a new daily weight-loss pill, led to significant weight loss, with 18.4% of those on the highest dose losing 20% or more of their body weight.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential implications and future considerations regarding orforglipron?

Orforglipron's potential approval by the FDA and other regulatory bodies could greatly expand access to effective weight-loss treatment for millions. However, longer-term studies are necessary to assess the long-term effects and potential side effects, ensuring its safety and efficacy over extended periods.

news.sky.com

🌐 85% Global Worthiness

Aug 15, 01:21

Mounjaro UK Price Soars 170% Amid US Cost-Cutting Push

Eli Lilly announced a 170% price hike for its weight-loss drug Mounjaro in the UK, increasing the highest dose to £330 per month, to align UK pricing with other European markets and lower US costs, though the NHS remains unaffected.

Mounjaro UK Price Soars 170% Amid US Cost-Cutting Push

Eli Lilly announced a 170% price hike for its weight-loss drug Mounjaro in the UK, increasing the highest dose to £330 per month, to align UK pricing with other European markets and lower US costs, though the NHS remains unaffected.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the 170% price increase of Mounjaro in the UK?

The UK price of Mounjaro, a weight-loss drug, will increase by up to 170% to £330 per month for the highest dose, impacting private healthcare providers but not the NHS. This follows the US manufacturer, Eli Lilly's, decision to align UK prices more closely with those in other European markets. The price hike is intended to lower costs in the US.

us.cnn.com

🌐 85% Global Worthiness

Aug 7, 16:17

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...

Eli Lilly's Oral GLP-1 Pill Shows Significant Weight Loss in Phase 3 Trial

Eli Lilly announced positive Phase 3 trial results for its oral GLP-1 obesity drug, orforglipron, showing a 12.4% average weight loss in 3,127 obese adults (excluding diabetics) after 72 weeks, with 59.6% losing at least 10% of their body weight and 39.6% losing at least 15%, and fewer cardiovascula...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of Eli Lilly's orforglipron Phase 3 trial results on obesity treatment?

In a Phase 3 trial, Eli Lilly's orforglipron, a once-daily oral GLP-1 pill, facilitated a 12.4% average weight reduction in obese adults over 72 weeks. This involved 3,127 participants with at least one weight-related health issue, excluding diabetes. The highest dose resulted in 59.6% achieving 10% weight loss and 39.6% achieving 15% weight loss.

arabic.euronews.com

🌐 85% Global Worthiness

Jul 26, 10:09

EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Monitoring

The European Medicines Agency conditionally approved Eli Lilly's Donanemab for early-stage Alzheimer's patients with one or zero copies of a specific gene, reversing its initial rejection due to the risk of fatal brain swelling and bleeding, mirroring a similar approval process for Lecanemab.

EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Monitoring

The European Medicines Agency conditionally approved Eli Lilly's Donanemab for early-stage Alzheimer's patients with one or zero copies of a specific gene, reversing its initial rejection due to the risk of fatal brain swelling and bleeding, mirroring a similar approval process for Lecanemab.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the EMA's decision on Donanemab compare to its previous decision on Lecanemab, and what factors influenced the conditional approvals?

Donanemab, developed by Eli Lilly, showed a 35% slowing of Alzheimer's symptoms in an 18-month trial. However, three patients died due to ARIA (amyloid-related imaging abnormalities), prompting restrictions. The EMA's conditional approval prioritizes patient safety by limiting access to patients without the risk gene or with only one copy, mandating close monitoring to detect and treat ARIA.

theguardian.com

🌐 75% Global Worthiness

May 22, 10:12

Australia Approves New Alzheimer's Drug, but High Cost and Limited Access Remain

Australia approved donanemab for early-stage Alzheimer's, offering a 33% slower decline rate but costing $80,000 and impacting only 10-20% of dementia patients due to genetic profile and other requirements; the drug's access is further limited by Medicare and Pharmaceutical Benefits Scheme exclusion...

Australia Approves New Alzheimer's Drug, but High Cost and Limited Access Remain

Australia approved donanemab for early-stage Alzheimer's, offering a 33% slower decline rate but costing $80,000 and impacting only 10-20% of dementia patients due to genetic profile and other requirements; the drug's access is further limited by Medicare and Pharmaceutical Benefits Scheme exclusion...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What factors limit the widespread use of donanemab, and what are the broader implications for Alzheimer's disease management?

Donanemab's approval marks the first Alzheimer's treatment impacting disease progression in 25 years, but its effectiveness is constrained by strict eligibility criteria and high costs. The drug targets amyloid proteins, slowing decline, but requires genetic testing and MRI scans, excluding many patients and increasing expenses.

cincodias.elpais.com

🌐 75% Global Worthiness

May 2, 10:12

Novo Nordisk's Telemedicine Deal to Counter Eli Lilly in Obesity Drug Market

Novo Nordisk partnered with Hims & Hers Health to sell its Wegovy weight-loss drug through telemedicine platforms at discounted prices, directly competing with Eli Lilly's Zepbound strategy amid insurance coverage challenges and following a recent stock decline of over 30% since January 2025, after ...

Novo Nordisk's Telemedicine Deal to Counter Eli Lilly in Obesity Drug Market

Novo Nordisk partnered with Hims & Hers Health to sell its Wegovy weight-loss drug through telemedicine platforms at discounted prices, directly competing with Eli Lilly's Zepbound strategy amid insurance coverage challenges and following a recent stock decline of over 30% since January 2025, after ...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What immediate impact will Novo Nordisk's telemedicine partnership have on its revenue and market share in the obesity drug sector?

Novo Nordisk, facing investor uncertainty due to concerns about future treatments, announced a new agreement with Hims & Hers Health to sell Wegovy via telemedicine platforms at reduced prices. This follows Eli Lilly's similar strategy with Zepbound, highlighting the growing use of telemedicine to increase sales amid challenges in securing insurance coverage for obesity drugs. This partnership aims to boost revenue and compete with Eli Lilly.

Showing 1 to 12 of 27 results